Medis

What Medis does

Medis ehf is a privately held Icelandic pharmaceutical out-licensing company, founded in 1985 and headquartered in Hafnarfjörður, Iceland, that operates as a separately run business unit within Teva Pharmaceutical Industries Ltd. The company specializes in developing generic pharmaceutical products in-house, primarily tablets, capsules, and injections, with a portfolio of approximately 185-200+ products spanning oncology, cardiovascular, antiinfectives, nervous system, alimentary tract and metabolism, blood and blood forming organs, respiratory, musculo-skeletal, genito-urinary, and systemic hormonal therapeutic areas. Its core technology and asset base comprise comprehensive registration dossiers prepared in eCTD, ANDA, and Canadian formats, plus serialization services supporting compliance with the EU Falsified Medicines Directive, all backed by Teva's development and manufacturing infrastructure.

Medis monetizes through a B2B out-licensing model that combines upfront licensing fees, ongoing royalties, and product supply agreements with third-party pharmaceutical companies and marketing authorization holders globally. It supports over 400 marketing authorization holders and more than 5,500 marketing authorizations across 100+ countries, delivered through a dedicated enterprise field sales motion in which each customer is assigned a business development manager and a customer experience manager, supported by a 24/7 ERP-integrated online customer portal (Medis Now). Regional teams and offices in Canada, Italy, Spain, Brazil, Australia, and the UAE cover Europe, North America, LATAM, MENA, and Oceania, with active participation in DCAT Week and CPhI events for BD lead generation. All production facilities are GMP-approved, and Medis holds no AI/ML capabilities, with technology focused on regulatory dossier preparation, serialization, and digital customer operations.

Name

Medis

Legal name

Medis ehf

Website

https://medis.is

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

101–250 employees

Short description

Medis is an Icelandic pharmaceutical out-licensing company, founded in 1985 and backed by Teva, that develops generic tablets, capsules, and injections in-house and licenses them to 400+ marketing authorization holders across 100+ countries. It generates revenue through licensing fees, royalties, and product supply agreements supported by dedicated BD/CX teams and the Medis Now online portal.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical out-licensing
• Regulatory dossiers
• Generic drug manufacturing
• Pharmaceutical supply chain

Headquarters

HQ city

Hafnarfjörður

HQ country

Iceland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Licensing: Medis out-licenses generic pharmaceutical products to third-party pharmaceutical companies worldwide. The company develops products in-house and provides regulatory support, manufacturing, and supply. Revenue is generated through product licensing agreements with upfront fees and ongoing royalties.
2. Pharmaceutical Product Supply: Supply of generic pharmaceutical products including tablets, capsules, and injections to licensed partners. Revenue generated through product sales under supply agreements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Medis out-licenses a portfolio of 200+ generic pharmaceutical products (tablets, capsules, injections, oral liquids) to third-party pharmaceutical companies worldwide. The company develops products in-house and provides comprehensive regulatory dossiers (ANDAs, eCTDs, Canadian dossiers), manufacturing, serialization, and supply chain services, supporting marketing authorizations in 100+ countries. Strong focus on oncology and metabolic therapeutic areas.

Product overview

Medis is a pharmaceutical out-licensing company offering a unified platform of generic pharmaceutical products and services. The core offering is a portfolio of 200+ generic pharmaceutical products (tablets, capsules, injections, oral liquids) across therapeutic areas including oncology, cardiovascular, antiinfectives, and nervous system. This is complemented by the Medis Now online customer portal for order management and reporting, supported by registration dossiers, regulatory affairs services, business development management, customer experience support, launch coordination, and supply chain management services. The company operates as part of Teva Pharmaceutical Industries Ltd., drawing on their development and manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Products Portfolio Broad portfolio of 200+ generic pharmaceutical products in tablets, capsules, injections, oral liquids, and modified release formulations covering oncology, cardiovascular, antiinfectives, nervous system, alimentary tract and metabolism, blood and blood forming organs, respiratory systems, musculo-skeletal system, genito-urinary system, and systemic hormonal preparations. Licensed to third-party pharmaceutical companies worldwide.
• Medis Now Online Customer Portal 24/7 online customer portal enabling customers to place orders, view order histories, access reports, graphs, and live data on orders, download invoices and documents, and monitor forecast accuracy. Directly connected to Medis resource planning systems.
• Registration Dossiers
• Regulatory Affairs Services
• Serialization Services
• Business Development Services
• Customer Experience (CX) Services
• Launch Coordination Services
• Supply Chain Management

Quantifiable outcome

• Regulatory approvals secured prior to patent expiry
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sandoz (Novartis): Large global generic and biosimilar pharmaceutical division of Novartis, with finished generics across virtually all therapeutic areas plus biologics/biosimilars. Comparable as a global generic developer/supplier across all of Medis' target therapeutic and geographic segments.
• Teva Pharmaceutical Industries Ltd. Parent company of Medis and one of the world's largest generic pharmaceutical manufacturers with global manufacturing, regulatory, and distribution infrastructure across essentially every therapeutic area and major market. Included as the parent incumbent that defines Medis' manufacturing and capital backbone.
• Aurobindo Pharma Limited: Large Indian-headquartered generic and specialty pharmaceutical manufacturer with broad finished generics (oral solids, injectables) supplied globally through partner/distribution channels. Comparable in finished-generic supply model and as a cost-competitive competitor in Medis' served markets.

Direct peers

• Gedeon Richter Plc. Hungarian-based specialty and generic pharmaceutical company with international out-licensing, finished-dose generics (tablets, capsules, injectables), and substantial regulatory dossier expertise across markets. Strong functional overlap with Medis in B2B generic licensing and supply.
• Alvotech: Biosimilar-focused company that develops products in-house and out-licenses them to commercial partners for regulatory, manufacturing, and supply purposes across multiple regions. The capital-light out-licensing model is closely analogous to Medis' generic out-licensing approach.
• Apotex Inc. Canadian-headquartered generic pharmaceutical developer and manufacturer with a large finished generics portfolio and international out-licensing/sourcing operations. Directly comparable as a generic out-licensor with regulatory dossiers and supply across multiple countries.
• Stada Arzneimittel AG: Major European generic and specialty pharmaceutical company that out-licenses and supplies generic products (including specialty generics) to partner companies, with a multi-country commercial footprint. Highly comparable to Medis' B2B generic out-licensing and supply model.
• Polpharma Biuro Handlowe: Polish-based generic pharmaceutical company with vertical integration from API to finished dosage forms, supplying tablets, capsules, and injectables to international partners. Comparable finished-generic, multi-market supply model with strong European presence.
• Hikma Pharmaceuticals PLC: Specialty and generic pharmaceutical company with strong MENA heritage that develops, licenses, and supplies a broad portfolio of finished-dose generics globally. Comparable in product breadth (tablets, capsules, injectables), out-licensing/sales mix, and presence in markets Medis targets.
• KRKA, d.d., Novo Mesto: Slovenian generic pharmaceutical manufacturer with broad finished-dose generics portfolio (tablets, capsules, injectables) that licenses and supplies products internationally across 100+ markets — a near-direct comparator in product form factors, out-licensing/revenue model, and geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sharer/sharer.php?u=https://www.medis.is
• LinkedInlinkedin.com/company/medis-ehf

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medis